Publicaciones en las que colabora con Alfredo Carrato Mena (18)

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

2012

  1. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

2011

  1. Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma

    Cancer Chemotherapy and Pharmacology, Vol. 67, Núm. 1, pp. 75-82

  2. Treatment recommendations for metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 13, Núm. 3, pp. 162-178

2009

  1. Phase II Trial of Preoperative Irinotecan-Cisplatin Followed by Concurrent Irinotecan-Cisplatin and Radiotherapy for Resectable Locally Advanced Gastric and Esophagogastric Junction Adenocarcinoma

    International Journal of Radiation Oncology Biology Physics, Vol. 75, Núm. 5, pp. 1430-1436

2006

  1. Guides for adjuvant treatment of colon cancer

    Clinical and Translational Oncology, Vol. 8, Núm. 2, pp. 98-102

2005

  1. Capecitabine as adjuvant treatment for stage III colon cancer

    New England Journal of Medicine, Vol. 352, Núm. 26, pp. 2696-2704

  2. Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer

    Clinical Colorectal Cancer, Vol. 4, Núm. 6, pp. 384-389

2004

  1. Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer

    Annals of Oncology, Vol. 15, Núm. 4, pp. 559-567

2003

  1. Irinotecan (CPT-11) in Metastatic Colorectal Cancer Patients Resistant to 5-Fluorouracil (5-FU): A Phase II Study

    Methods and Findings in Experimental and Clinical Pharmacology, Vol. 25, Núm. 8, pp. 639-643

2000

  1. Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer

    Clinical and Translational Oncology, Vol. 2, Núm. 3, pp. 154-158

1999

  1. UFT Plus or Minus Calcium Folinate for Metastatic Golorectal Cancer in Older Patients

    ONCOLOGY, Vol. 13, Núm. 7 SUPPL., pp. 35-40

1998

  1. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study

    Annals of Oncology, Vol. 9, Núm. 7, pp. 727-731

  2. Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas a phase II trial

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 21, Núm. 2, pp. 151-154

1996

  1. Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial

    Annals of Oncology, Vol. 7, Núm. 6, pp. 581-585

  2. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).

    The Journal of infusional chemotherapy, Vol. 6, Núm. 3, pp. 118-122

1995

  1. A phase II trial of weekly high dose continuous infusion 5‐fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

    Cancer, Vol. 76, Núm. 4, pp. 559-563

1992

  1. Etoposide (E) + epirebicin (E) + cisplatin (P) combination chemotherapy (EEP) In advanced gastric cancer: Negative impact on clinical outcome: On behalf of the Spanish cooperative group for GI tumor therapy (T.T.D.)

    Annals of Oncology, Vol. 3, Núm. 10, pp. 861-863